Stage III Esophageal Squamous Cell Carcinoma Patients With Three-Dimensional Conformal or Intensity-Modulated Radiotherapy: A Multicenter Retrospective Study
Qin Qin,Xiaolin Ge,Xin Wang,Lan Wang,Chen Li,Junqiang Chen,Xiaomin Wang,Yidian Zhao,Wencheng Zhang,Ping Wang,Qingsong Pang,Kaixian Zhang,Ling Li,Miaomiao Hu,Chongli Hao,Gaofeng Li,Yonggang Xu,Xueying Qiao,Zhiguo Zhou,Shuchai Zhu,Wenbin Shen,Yati Wang,Na Lu,Miaoling Liu,Shuai Qie,Chun Han,Zefen Xiao,Xinchen Sun
DOI: https://doi.org/10.3389/fonc.2020.580450
IF: 4.7
2020-10-06
Frontiers in Oncology
Abstract:<b>Aim:</b> To evaluate long-term outcome and prognostic factors of stage III esophageal cancer after definitive radiotherapy using three dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) techniques. <b>Methods:</b> Patients with T3N1M0/T4N0-1M0 esophageal squamous cell carcinoma (ESCC) treated with definitive radiotherapy from 2002 to 2016 in 10 Chinese medical centers were retrospectively analyzed. Overall survival (OS) and progression-free survival (PFS) rates were calculated. Prognostic factors were analyzed by Log-rank test and multivariable Cox model. <b>Results:</b> Survival data of 1,450 patients were retrospectively collected. With a median follow-up time of 65.9 months, 1-, 3-, and 5-year OS rates were 69.3, 36.7, and 27.7%, respectively, and PFS rates were 58.6, 32.7, and 27.4%, respectively. Univariable analyses showed that gender, age, lesion location, lesion length, largest tumor diameter, lymph node metastasis, gross tumor volume, EQD2, short-term response, and concurrent chemotherapy were prognostic factors for OS. Multivariable analyses showed that lesion location, T-classification, GTV size, EQD2, and short-term response to RT were independent prognostic factors for OS, and tumor diameter, GTV size, and short-term response were independent prognostic factors for PFS. <b>Conclusions:</b> This study demonstrated that definitive radiotherapy using 3DCRT and IMRT provides promising outcomes for locally advanced ESCC.
oncology